GlassScriptPhysician profile
Bhavesh D Gala
NPI 1558416776
$4,177.10
in general payments reported to CMS, 2019-2025
30 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,356 · 2020: $1,162 · 2021: $741 · 2022: $92.44 · 2023: $134 · 2024: $207 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $732.67 | 2019-2023 | Lokelma |
| Amgen INC. | $550.19 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $400.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $384.26 | 2019-2024 | |
| Pfizer INC. | $322.00 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.63 | 2019-2021 | |
| Abbott Laboratories | $180.48 | 2019-2025 | Navitor |
| E.R. Squibb & Sons, L.L.C. | $156.08 | 2020-2024 | Camzyos |
| Inari Medical, INC. | $146.60 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.84 | 2019-2020 | |
| Medtronic, INC. | $123.97 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Irhythm Technologies, INC. | $121.00 | 2019-2020 | |
| Amarin Pharma, INC. | $88.82 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $77.83 | 2019-2020 | |
| Abiomed | $76.46 | 2021-2025 | Impella |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $63.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.74 | 2022-2023 | Verquvo |
| Medtronic Vascular, INC. | $51.23 | 2019-2020 | |
| Chiesi USA, INC. | $44.66 | 2023-2025 | Kengreal |
| Cardiovascular Systems INC. | $42.82 | 2021 | |
| Kestra Medical Technology Services, INC. | $38.55 | 2023 | Assure Wcd |
| Astellas Pharma US INC | $37.92 | 2020-2021 | |
| Esperion Therapeutics, INC. | $22.50 | 2020 | |
| Octapharma USA, INC. | $21.04 | 2025 | Fibryga |
| Scpharmaceuticals INC. | $19.81 | 2025 | |
| Boston Scientific Corporation | $15.00 | 2020 | |
| Hikma Pharmaceuticals USA | $14.67 | 2019 | |
| Gilead Sciences, INC. | $14.05 | 2019 | |
| Cardinal Health 200 LLC | $12.48 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavesh Gala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.